Early Phase Investigational Therapeutics, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, USA.
Ann Pharmacother. 2013 Jul-Aug;47(7-8):1055-63. doi: 10.1345/aph.1R769. Epub 2013 Jun 11.
To evaluate everolimus drug-drug and drug-food interactions, with an emphasis on patients with cancer.
Literature was accessed through PubMed (1990-March 2013) using Boolean combinations of the terms drug interactions, herb-drug interactions, food-drug interactions, everolimus, antineoplastic agents, hormonal, and breast neoplasms. In addition, reference citations from publications and the prescribing information for everolimus were reviewed.
All articles published in English, including human, animal, and in vitro studies, identified from the data sources were included.
Patients with cancer are at increased risk for drug interactions because of the multiple medications they are prescribed to treat their disease and comorbid conditions. Everolimus, an oral mammalian target of rapamycin (mTOR) inhibitor, is indicated for the treatment in adults with progressive neuroendocrine tumors of pancreatic origin that are unresectable, locally advanced, or metastatic; adults with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib; and, recently, postmenopausal women with advanced hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole. As its use increases among patients with cancer, clinicians must be knowledgeable about potential drug and/or food/nutrient interactions and the mechanisms by which these interactions occur, to mitigate and prevent unwanted reactions and ensure patient safety.
Everolimus is a widely used oral mTOR inhibitor that has the potential for drug interactions that may affect therapeutic outcomes, produce toxicities, or both. This article provides a review of evidence-based literature, along with the prescribing information, to educate clinicians on the significance of these drug interactions and their impact on management with everolimus.
评估依维莫司的药物相互作用和药物-食物相互作用，重点关注癌症患者。
通过 PubMed（1990 年至 2013 年 3 月）使用药物相互作用、草药-药物相互作用、食物-药物相互作用、依维莫司、抗肿瘤药、激素和乳腺肿瘤等术语的布尔组合检索文献。此外，还查阅了出版物的参考文献和依维莫司的说明书。
从资料来源中包括所有以英文发表的文章，包括人体、动物和体外研究。
由于癌症患者需要治疗疾病和合并症而开具的多种药物，因此他们发生药物相互作用的风险增加。依维莫司是一种口服哺乳动物雷帕霉素靶蛋白（mTOR）抑制剂，适用于治疗无法切除、局部晚期或转移性的胰腺来源的进展性神经内分泌肿瘤；接受舒尼替尼或索拉非尼治疗失败的晚期肾细胞癌患者；最近，用于治疗接受来曲唑或阿那曲唑治疗失败的绝经后妇女的晚期激素受体阳性、人表皮生长因子受体 2 阴性乳腺癌，与依西美坦联合使用。随着依维莫司在癌症患者中的应用增加，临床医生必须了解潜在的药物和/或食物/营养素相互作用以及这些相互作用发生的机制，以减轻和预防不良反应，确保患者安全。
依维莫司是一种广泛应用的口服 mTOR 抑制剂，具有发生可能影响治疗结果、产生毒性或两者兼有的药物相互作用的潜力。本文综述了循证文献以及说明书，使临床医生了解这些药物相互作用的意义及其对依维莫司治疗管理的影响。
